Ionis Pharmaceuticals Inc
NASDAQ:IONS

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Watchlist
Price: 42.25 USD 0.24% Market Closed
Market Cap: 6.7B USD

Net Margin
Ionis Pharmaceuticals Inc

-63.9%
Current
-41%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-63.9%
=
Net Income
-458m
/
Revenue
717.3m

Net Margin Across Competitors

Ionis Pharmaceuticals Inc
Glance View

Market Cap
6.7B USD
Industry
Biotechnology

In the realm of pharmaceutical innovation, Ionis Pharmaceuticals Inc. has carved a niche defined by its pioneering efforts in antisense technology. Founded in 1989, Ionis stands as a trailblazer in the development of RNA-targeted therapies, which deviate from the traditional drug development pathways by focusing on genetic solutions. The company specializes in antisense oligonucleotides—short, synthetic strands of DNA or RNA designed to bind selectively to specific messenger RNA (mRNA). By doing so, they aim to modulate the expression of genes associated with various diseases. This unique approach allows Ionis to address ailments at the genetic level, potentially preventing the production of disease-causing proteins, thus offering alternative therapeutic options for serious diseases. Ionis Pharmaceuticals monetizes its scientific breakthroughs through a diverse revenue stream model. It engages in multiple collaborative partnerships with major pharmaceutical companies, such as Biogen and AstraZeneca, which provide upfront payments, milestone-based fees, and royalties on lucrative antisense drugs that emerge from these alliances. Furthermore, Ionis holds an extensive internal pipeline, advancing proprietary drugs through various stages of research and clinical trials. By strategically balancing in-house projects with external collaborations, Ionis capitalizes on its innovative platform while mitigating financial risks. This dual-strategy not only sustains the company financially but positions it at the forefront of personalized medicine, potentially revolutionizing the landscape of therapeutic development.

IONS Intrinsic Value
45.15 USD
Undervaluation 6%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-63.9%
=
Net Income
-458m
/
Revenue
717.3m
What is the Net Margin of Ionis Pharmaceuticals Inc?

Based on Ionis Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -63.9%.

Back to Top